A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

NP001

Low dose of NP001

DRUG

NP001

High dose of NP001

DRUG

Placebo

normal saline

Trial Locations (17)

10032

Columbia University, New York

13210

SUNY Upstate Medical University, Syracuse, Syracuse

27705

Duke University, Dept of Neurology, Durham

28207

Carolinas Medical Center, Charlotte

30322

The Emory Clinic, Atlanta

32224

Mayo Clinic, Jacksonville, Jacksonville

44195

Cleveland Clinic, Cleveland

66160

University of Kansas Medical Center, Landon Center on Aging, Kansas City

77030

Methodist Hospital Research Institute, Methodist Neurologic Institute, Houston

85259

Mayo Clinic, Scottsdale, Scottsdale

90095

UCLA, Los Angeles

94115

California Pacific Med Center Forbes Norris MDA/ALS Research and Treatment Center, San Francisco

97213

Providence ALS Center, Portland

98531

Providence Saint Peter Hospital, Centralia

92868-4281

UC, Irvine, Irvine

40536-0284

University of Kentucky, Department of Neurology, Lexington

02129

Massachusetts General Hospital, Charlestown

All Listed Sponsors
lead

Neuraltus Pharmaceuticals, Inc.

INDUSTRY